Cargando…

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.

Detalles Bibliográficos
Autores principales:	König, Marton, Torgauten, Hilde Marie, Tran, The Trung, Holmøy, Trygve, Vaage, John Torgils, Lund-Johansen, Fridtjof, Nygaard, Gro Owren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787678/ https://www.ncbi.nlm.nih.gov/pubmed/35072702 http://dx.doi.org/10.1001/jamaneurol.2021.5109

Ejemplares similares

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
por: König, Marton, et al.
Publicado: (2023)

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
por: Wolf, Asia-Sophia, et al.
Publicado: (2023)

Trends in seroprevalence of SARS‐CoV‐2 and infection fatality rate in the Norwegian population through the first year of the COVID‐19 pandemic
por: Tunheim, Gro, et al.
Publicado: (2021)

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination
por: Riise, Jon, et al.
Publicado: (2022)

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022)

Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
por: Kared, Hassen, et al.
Publicado: (2022)

Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
por: Tunheim, Gro, et al.
Publicado: (2022)

Tuberculin responses after BCG vaccination predict amyotrophic lateral sclerosis risk
por: Nakken, Ola, et al.
Publicado: (2023)

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
por: Joergensen, Kristin K., et al.
Publicado: (2022)

A strong case for third-party testing
por: Lund-Johansen, Fridtjof
Publicado: (2023)

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
por: Kared, Hassen, et al.
Publicado: (2023)

Robust spike-specific CD4(+) and CD8(+) T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study
por: Federico, Lorenzo, et al.
Publicado: (2023)

Humoral Response After 6 or More Successive Doses of SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients—Should We Keep Vaccinating?
por: Åsberg, Anders, et al.
Publicado: (2023)

Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!
por: Midtvedt, Karsten, et al.
Publicado: (2021)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study
por: Hovd, Markus, et al.
Publicado: (2023)

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
por: Jyssum, Ingrid, et al.
Publicado: (2022)

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
por: Søraas, Arne, et al.
Publicado: (2022)

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
por: Syversen, Silje Watterdal, et al.
Publicado: (2022)

Symptoms of fatigue and depression is reflected in altered default mode network connectivity in multiple sclerosis
por: Høgestøl, Einar August, et al.
Publicado: (2019)

High‐throughput sequencing of immune repertoires in multiple sclerosis
por: Lossius, Andreas, et al.
Publicado: (2016)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation
por: Lossius, Andreas, et al.
Publicado: (2012)

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2022)

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2023)

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2022)

Letter to the Editor: Immunogenicity After the Third Dose of COVID-19 Vaccine in Cardiac Transplantation
por: Rahman, Afsana, et al.
Publicado: (2023)

Immunogenicity of third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: An open question
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study
por: Nakken, Ola, et al.
Publicado: (2022)

Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model
por: Kalnin, Kirill V., et al.
Publicado: (2022)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
por: Giuliano, Anna, et al.
Publicado: (2023)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018)

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study
por: Høgestøl, Einar August, et al.
Publicado: (2021)

An Update on Vitamin D and Disease Activity in Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2019)

Vaccine for immunizing cattle against lungworm comprising live immunogenic attenuated Dictyocaulus viviparus third stage larvae
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_r5kju92s79okdr5o506f40hbvq